查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球法布裡病療法市場規模：按治療類型、最終用途、行業分析、價格趨勢、區域展望、增長潛力、競爭市場份額和預測（2022-2030 年）
市場調查報告書
商品編碼
1128103

全球法布裡病療法市場規模：按治療類型、最終用途、行業分析、價格趨勢、區域展望、增長潛力、競爭市場份額和預測（2022-2030 年）

Fabry Disease Treatment Market Size By Treatment Type (Enzyme Replacement Therapy, By End-use }, Chaperone Therapy), By Industry Analysis Report, Price Trends, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2022 - 2030
出版日期: | 出版商: Global Market Insights Inc. | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

全球法布裡病治療市場規模預計將從 2022 年到 2030 年顯著增加，因為越來越多的舉措有助於疾病的早期診斷和治療。

促進篩查疑似法布裡病和其他疾病的項目的啟動預計將有助於預測期內的市場擴張。

按地區劃分，預計到 2030 年，歐洲的利潤將顯著增長。這是由於成年人口的增長和遲發性法布裡病症狀患病率的潛在增加。它還預計在預測期內亞太地區將有豐厚的收入機會。該地區的市場增長是由對醫療基礎設施擴建項目的關注推動的。

本報告研究了全球法布裡病治療市場，並提供了市場規模和預測、市場動態、按細分市場/地區分列的市場分析、競爭格局和主要參與者概況等信息。

內容

第一章調查方法及範圍

  • 市場定義
  • 基本假設和工作
  • 預測參數
  • 數據驗證
  • 來源

第 2 章執行摘要

  • 法布裡病治療行業總結（2017-2030，價值）
    • 業務趨勢
    • 治療類型的趨勢
    • 區域趨勢

第 3 章法布裡病治療行業注意事項

  • 行業細分
  • 行業情況（2017-2030，金額）
  • 影響行業的因素
    • 驅動程序
    • 行業的潛在風險和挑戰
  • 增長分析
    • 按治療
  • COVID-19 影響分析
  • 未來市場趨勢
  • 技術格局
  • 價格分析
  • 品牌分析
  • 差距分析
  • 產品線分析
  • 兌換場景
  • 監管狀況
  • 波特分析
  • 競爭格局（2021 年）
  • PESTLE 分析

第 4 章法布裡病治療市場：按治療類型分類

  • 主要細分市場的趨勢
  • □替代療法 (ERT)
    • 市場規模：按地區劃分（2017-2030 年，價值）
    • 按藥物類型
    • 按最終用途
  • 伴侶療法
    • 市場規模：按地區劃分（2017-2030 年，價值）

第 5 章法布裡病治療市場：按地區劃分

  • 主要區域趨勢
  • 北美
    • 市場規模：按國家/地區分類（2017-2030 年，價值）
    • 市場規模：按治療類型（2017-2030 年，價值）
    • 美國
    • 加拿大
  • 歐洲
    • 市場規模：按國家/地區分類（2017-2030 年，價值）
    • 市場規模：按治療類型（2017-2030 年，價值）
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 意大利
  • 亞太地區
    • 市場規模：按國家/地區分類（2017-2030 年，價值）
    • 市場規模：按治療類型（2017-2030 年，價值）
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 韓國
  • 其他地區
    • 市場規模：按治療類型（2017-2030 年，價值）

第 6 章公司簡介

  • 競爭信息中心（2021 年）
  • Sanofi
  • Takeda
  • Amicus Therapeutics
  • ISU Abaxis
  • JCR Pharmaceuticals Co Ltd.
Product Code: 4237

The global Fabry disease treatment market size is expected to increase considerably over 2022-2030, on account of the rising initiatives to support early-disease diagnosis and treatments. A notable example is an initiative launched by the National Kidney Foundation and the FSIG (Fabry Support & Information Group) to inform the U.S. FDA about the perspectives of living with Fabry disease.

Patients with rare genetic diseases are facing a challenging path to proper diagnosis due to low disease awareness. To reduce barriers to comprehensive testing methods, several projects have been developed worldwide. For example, Sanofi Genzyme and PerkinElmer Genomics launched the Lantern Project to facilitate the screening of suspected Fabry and other disorders, which is anticipated to contribute to market expansion over the projected timeframe.

The Fabry disease treatment industry is bifurcated in terms of treatment type and regional landscape.

Based on the treatment type, the market is segregated into chaperone therapy and enzyme replacement therapy (ERT). Among these, the chaperone therapy segment is set to account for a considerable market share by 2030. This is attributed to the capability of small-molecule chaperones to bind to active sites of mutant forms of the alpha-galactosidase A enzyme, stabilize them, and restore the function of the natural enzyme.

The binding and stabilization can help facilitate the proper trafficking of alpha-Gal A to the lysosomes, enabling the restoration of enzymatic activity of the mutant protein and lowering the rate of accumulation of glycolipids in organ cells. These benefits will likely encourage healthcare professionals to rely on chaperone therapy for Fabry disease diagnosis and in turn, drive the segmental expansion.

On the regional front, the Europe Fabry disease treatment industry is expected to register considerable revenue by 2030. This can be credited to the rising adult population and the potential increase in the prevalence of late-onset Fabry disease symptoms. According to data from Eurostat, the number of people aged 80 years and above is likely to grow by two and a half times between 2021 and 2100. Since elderly people are at higher risk of Fabry disease, this population rise may assert a positive influence on regional market trends.

Likewise, the Asia Pacific is also anticipated to emerge as a lucrative revenue pocket for the Fabry disease treatment market over the estimated timeline. The regional market growth is driven by the growing emphasis on healthcare infrastructure expansion projects.

For example, in October 2021, AIIB (Asian Infrastructure Investment Bank) announced its support for India, in its efforts to ramp up healthcare infrastructure facilities to meet future health challenges. AIIB also revealed its collaboration with the Indian government to form climate-resilient infrastructure projects. Initiatives such as these are expected to advance Fabry disease therapy and consequently foster regional Fabry disease treatment industry development over the years ahead.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market definitions
  • 1.2 Base estimates and working
  • 1.3 Forecast parameters
  • 1.4 Data validation
  • 1.5 Data sources
    • 1.5.1 Secondary
      • 1.5.1.1 Paid sources
      • 1.5.1.2 Unpaid sources
    • 1.5.2 Primary

Chapter 2 Executive Summary

  • 2.1 Fabry disease treatment industry 360 degree synopsis, 2017 - 2030 (USD Million)
    • 2.1.1 Business trends
    • 2.1.2 Treatment type trends
    • 2.1.3 Regional trends

Chapter 3 Fabry Disease Treatment Industry Insights

  • 3.1 Industry segmentation
  • 3.2 Industry landscape, 2017 - 2030 (USD Million)
  • 3.3 Industry impact forces
    • 3.3.1 Growth drivers
      • 3.3.1.1 Rising cases of Fabry disease across the globe
      • 3.3.1.2 Growing awareness among specialist and physicians
      • 3.3.1.3 Advancements in Fabry disease treatment therapies
      • 3.3.1.4 Rising health awareness and demand for early-stage diagnosis
    • 3.3.2 Industry pitfalls & challenges
      • 3.3.2.1 High treatment cost
  • 3.4 Growth potential analysis
    • 3.4.1 By treatment
  • 3.5 COVID- 19 impact analysis
  • 3.6 Future market trends
  • 3.7 Technology landscape
  • 3.8 Pricing analysis
  • 3.9 Brand analysis
  • 3.10 Gap analysis
  • 3.11 Product pipeline analysis
  • 3.12 Reimbursement scenario
  • 3.13 Regulatory landscape
    • 3.13.1 U.S.
    • 3.13.2 Europe
  • 3.14 Porter's Analysis
  • 3.15 Competitive landscape, 2021
    • 3.15.1 Company matrix analysis, 2021
    • 3.15.2 Company market share analysis, 2021
    • 3.15.3 Global
    • 3.15.4 North America
    • 3.15.5 Europe
    • 3.15.6 Asia Pacific
    • 3.15.7 Latin America
    • 3.15.8 MEA
  • 3.16 PESTLE Analysis

Chapter 4 Fabry Disease Treatment Market, By Treatment Type

  • 4.1 Key segment trends
  • 4.2 Enzyme Replacement Therapy (ERT)
    • 4.2.1 Market size, by region, 2017 - 2030 (USD Million)
    • 4.2.2 By Drug Type
      • 4.2.2.1 Agalidase Alpa
        • 4.2.2.1.1 Market size, by region, 2017 - 2030 (USD Million)
      • 4.2.2.2 Agalidase Beta
        • 4.2.2.2.1 Market size, by region, 2017 - 2030 (USD Million)
    • 4.2.3 By End-use
      • 4.2.3.1 Physician office
        • 4.2.3.1.1 Market size, by region, 2017 - 2030 (USD Million)
      • 4.2.3.2 Home settings
        • 4.2.3.2.1 Market size, by region, 2017 - 2030 (USD Million)
  • 4.3 Chaperone Therapy
    • 4.3.1 Market size, by region, 2017 - 2030 (USD Million)

Chapter 5 Fabry Disease Treatment Market, By Region

  • 5.1 Key regional trends
  • 5.2 North America
    • 5.2.1 Market size, by country, 2017 - 2030 (USD Million)
    • 5.2.2 Market size, by treatment type, 2017 - 2030 (USD Million)
      • 5.2.2.1 Market size, by drug type, 2017 - 2030 (USD Million)
      • 5.2.2.2 Market size, by end-use, 2017 -2030 (USD Million)
    • 5.2.3 U.S.
      • 5.2.3.1 Market size, by treatment type, 2017-2030 (USD Million)
        • 5.2.3.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
        • 5.2.3.1.2 Market size, by end-use, 2017 -2030 (USD Million)
    • 5.2.4 Canada
      • 5.2.4.1 Market size, by treatment type, 2017-2030 (USD Million)
        • 5.2.4.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
        • 5.2.4.1.2 Market size, by end-use, 2017 -2030 (USD Million)
  • 5.3 Europe
    • 5.3.1 Market size, by country, 2017 - 2030 (USD Million)
    • 5.3.2 Market size, by treatment type, 2017 - 2030 (USD Million)
      • 5.3.2.1 Market size, by drug type, 2017 - 2030 (USD Million)
      • 5.3.2.2 Market size, by end-use, 2017 -2030 (USD Million)
    • 5.3.3 Germany
      • 5.3.3.1 Market size, by treatment type, 2017-2030 (USD Million)
        • 5.3.3.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
        • 5.3.3.1.2 Market size, by end-use, 2017 -2030 (USD Million)
    • 5.3.4 UK
      • 5.3.4.1 Market size, by treatment type, 2017-2030 (USD Million)
        • 5.3.4.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
        • 5.3.4.1.2 Market size, by end-use, 2017 -2030 (USD Million)
    • 5.3.5 France
      • 5.3.5.1 Market size, by treatment type, 2017-2030 (USD Million)
        • 5.3.5.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
        • 5.3.5.1.2 Market size, by end-use, 2017 -2030 (USD Million)
    • 5.3.6 Spain
      • 5.3.6.1 Market size, by treatment type, 2017-2030 (USD Million)
        • 5.3.6.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
        • 5.3.6.1.2 Market size, by end-use, 2017 -2030 (USD Million)
    • 5.3.7 Italy
      • 5.3.7.1 Market size, by treatment type, 2017-2030 (USD Million)
        • 5.3.7.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
        • 5.3.7.1.2 Market size, by end-use, 2017 -2030 (USD Million)
  • 5.4 Asia Pacific
    • 5.4.1 Market size, by country, 2017 - 2030 (USD Million)
    • 5.4.2 Market size, by treatment type, 2017 - 2030 (USD Million)
      • 5.4.2.1 Market size, by drug type, 2017 - 2030 (USD Million)
      • 5.4.2.2 Market size, by end-use, 2017 -2030 (USD Million)
    • 5.4.3 Japan
      • 5.4.3.1 Market size, by treatment type, 2017-2030 (USD Million)
        • 5.4.3.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
        • 5.4.3.1.2 Market size, by end-use, 2017 -2030 (USD Million)
    • 5.4.4 China
      • 5.4.4.1 Market size, by treatment type, 2017-2030 (USD Million)
        • 5.4.4.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
        • 5.4.4.1.2 Market size, by end-use, 2017 -2030 (USD Million)
    • 5.4.5 India
      • 5.4.5.1 Market size, by treatment type, 2017-2030 (USD Million)
        • 5.4.5.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
        • 5.4.5.1.2 Market size, by end-use, 2017 -2030 (USD Million)
    • 5.4.6 Australia
      • 5.4.6.1 Market size, by treatment type, 2017-2030 (USD Million)
        • 5.4.6.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
        • 5.4.6.1.2 Market size, by end-use, 2017 -2030 (USD Million)
    • 5.4.7 South Korea
      • 5.4.7.1 Market size, by treatment type, 2017-2030 (USD Million)
        • 5.4.7.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
        • 5.4.7.1.2 Market size, by end-use, 2017 -2030 (USD Million)
  • 5.5 ROW
    • 5.5.1 Market size, by treatment type, 2017 - 2030 (USD Million)
      • 5.5.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
      • 5.5.1.2 Market size, by end-use, 2017 -2030 (USD Million)

Chapter 6 Company Profiles

  • 6.1 Competitive dashboard, 2021
  • 6.2 Sanofi
    • 6.2.1 Business Overview
    • 6.2.2 Financial Data
    • 6.2.3 Product Landscape
    • 6.2.4 Strategic Outlook
    • 6.2.5 SWOT Analysis
  • 6.3 Takeda
    • 6.3.1 Business Overview
    • 6.3.2 Financial Data
    • 6.3.3 Product Landscape
    • 6.3.4 Strategic Outlook
    • 6.3.5 SWOT Analysis
  • 6.4 Amicus Therapeutics
    • 6.4.1 Business Overview
    • 6.4.2 Financial Data
    • 6.4.3 Product Landscape
    • 6.4.4 Strategic Outlook
    • 6.4.5 SWOT Analysis
  • 6.5 ISU Abaxis
    • 6.5.1 Business Overview
    • 6.5.2 Financial Data
    • 6.5.3 Product Landscape
    • 6.5.4 Strategic Outlook
    • 6.5.5 SWOT Analysis
  • 6.6 JCR Pharmaceuticals Co Ltd.
    • 6.6.1 Business Overview
    • 6.6.2 Financial Data
    • 6.6.3 Product Landscape
    • 6.6.4 Strategic Outlook
    • 6.6.5 SWOT Analysis

Data Tables

  • TABLE 1. Global Fabry disease treatment market, 2017 - 2021 (USD Million)
  • TABLE 2. Global Fabry disease treatment market, 2022 - 2030 (USD Million)
  • TABLE 3. Global Fabry disease treatment market, by treatment type, 2017 - 2021 (USD Million)
  • TABLE 4. Global Fabry disease treatment market, by treatment type, 2022 - 2030 (USD Million)
  • TABLE 5. Global Fabry disease treatment market, by region, 2017 - 2021 (USD Million)
  • TABLE 6. Global Fabry disease treatment market, by region, 2022 - 2030 (USD Million)
  • TABLE 7. Industry impact forces
  • TABLE 8. Enzyme replacement therapy (ERT) market, by region, 2017 - 2021, (USD Million)
  • TABLE 9. Enzyme replacement therapy (ERT) market, by region, 2022 - 2030, (USD Million)
  • TABLE 10. Agalidase Alpha market, by region, 2017 - 2021, (USD Million)
  • TABLE 11. Agalidase Alpha market, by region, 2022 - 2030, (USD Million)
  • TABLE 12. Agalidase Beta market, by region, 2017 - 2021, (USD Million)
  • TABLE 13. Agalidase Beta market, by region, 2022 - 2030, (USD Million)
  • TABLE 14. Physician office market, by region, 2017 -2021 (USD Million)
  • TABLE 15. Physician office market, by region, 2022 -2030 (USD Million)
  • TABLE 16. End-use market, by region, 2017 -2021 (USD Million)
  • TABLE 17. End-use market, by region, 2017 -2021 (USD Million)
  • TABLE 18. Chaperone therapy market, by region, 2017 - 2021, (USD Million)
  • TABLE 19. Chaperone therapy market, by region, 2022 - 2030, (USD Million)
  • TABLE 20. North America Fabry disease treatment market, by country, 2017-2021, (USD Million)
  • TABLE 21. North America Fabry disease treatment market, by country, 2022-2030, (USD Million)
  • TABLE 22. North America Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
  • TABLE 23. North America Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
  • TABLE 24. North America enzyme replacement therapy (ERT) market, by drug type, 2017-2021, (USD Million)
  • TABLE 25. North America enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
  • TABLE 26. North America enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
  • TABLE 27. North America enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)
  • TABLE 28. U.S. Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
  • TABLE 29. U.S. Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
  • TABLE 30. U.S. enzyme replacement therapy (ERT) market, by drug type, 2017-2021, (USD Million)
  • TABLE 31. U.S. enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
  • TABLE 32. U.S. enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
  • TABLE 33. U.S. enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)
  • TABLE 34. Canada Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
  • TABLE 35. Canada Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
  • TABLE 36. Canada enzyme replacement therapy (ERT) market, by drug type, 2017-2021, (USD Million)
  • TABLE 37. Canada enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
  • TABLE 38. Canada enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
  • TABLE 39. Canada enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)
  • TABLE 40. Europe Fabry disease treatment market, by country, 2017-2021, (USD Million)
  • TABLE 41. Europe Fabry disease treatment market, by country, 2022-2030, (USD Million)
  • TABLE 42. Europe Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
  • TABLE 43. Europe Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
  • TABLE 44. Europe enzyme replacement therapy (ERT) market, by drug type, 2017-2021, (USD Million)
  • TABLE 45. Europe enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
  • TABLE 46. Europe enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
  • TABLE 47. Europe enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)
  • TABLE 48. Germany Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
  • TABLE 49. Germany Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
  • TABLE 50. Germany enzyme replacement therapy (ERT) market, by drug type, 2017-2021, (USD Million)
  • TABLE 51. Germany enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
  • TABLE 52. Germany enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
  • TABLE 53. Germany enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)
  • TABLE 54. UK Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
  • TABLE 55. UK Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
  • TABLE 56. UK enzyme replacement therapy (ERT) market, by drug type, 2017-2021, (USD Million)
  • TABLE 57. UK enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
  • TABLE 58. UK enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
  • TABLE 59. UK enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)
  • TABLE 60. France Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
  • TABLE 61. France Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
  • TABLE 62. France enzyme replacement therapy (ERT) market, by drug type, 2017-2021, (USD Million)
  • TABLE 63. France enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
  • TABLE 64. France enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
  • TABLE 65. France enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)
  • TABLE 66. Spain Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
  • TABLE 67. Spain Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
  • TABLE 68. Spain enzyme replacement therapy (ERT) market, by drug type, 2017-2021, (USD Million)
  • TABLE 69. Spain enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
  • TABLE 70. Spain enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
  • TABLE 71. Spain enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)
  • TABLE 72. Italy Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
  • TABLE 73. Italy Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
  • TABLE 74. Italy enzyme replacement therapy (ERT) market, by drug type, 2017 -2021, (USD Million)
  • TABLE 75. Italy enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
  • TABLE 76. Italy enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
  • TABLE 77. Italy enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)
  • TABLE 78. Asia Pacific Fabry disease treatment market, by country, 2017-2021, (USD Million)
  • TABLE 79. Asia Pacific Fabry disease treatment market, by country, 2022-2030, (USD Million)
  • TABLE 80. Asia Pacific Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
  • TABLE 81. Asia Pacific Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
  • TABLE 82. Asia Pacific enzyme replacement therapy (ERT) market, by drug type, 2017-2021, (USD Million)
  • TABLE 83. Asia Pacific enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
  • TABLE 84. Asia Pacific enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
  • TABLE 85. Asia Pacific enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)
  • TABLE 86. Japan Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
  • TABLE 87. Japan Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
  • TABLE 88. Japan enzyme replacement therapy (ERT) market, by drug type, 2017-2021, (USD Million)
  • TABLE 89. Japan enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
  • TABLE 90. Japan enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
  • TABLE 91. Japan enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)
  • TABLE 92. China Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
  • TABLE 93. China Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
  • TABLE 94. China enzyme replacement therapy (ERT) market, by drug type, 2017-2021, (USD Million)
  • TABLE 95. China enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
  • TABLE 96. China enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
  • TABLE 97. China enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)
  • TABLE 98. India Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
  • TABLE 99. India Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
  • TABLE 100. India enzyme replacement therapy (ERT) market, by drug type, 2017-2021, (USD Million)
  • TABLE 101. India enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
  • TABLE 102. India enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
  • TABLE 103. India enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)
  • TABLE 104. Australia Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
  • TABLE 105. Australia Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
  • TABLE 106. Australia enzyme replacement therapy (ERT) market, by drug type, 2017-2021, (USD Million)
  • TABLE 107. Australia enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
  • TABLE 108. Australia enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
  • TABLE 109. Australia enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)
  • TABLE 110. South Korea Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
  • TABLE 111. South Korea Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
  • TABLE 112. South Korea enzyme replacement therapy (ERT) market, by drug type, 2017 -2021, (USD Million)
  • TABLE 113. South Korea enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
  • TABLE 114. South Korea enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
  • TABLE 115. South Korea enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)
  • TABLE 116. ROW Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
  • TABLE 117. ROW Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
  • TABLE 118. ROW enzyme replacement therapy (ERT) market, by drug type, 2017 -2021, (USD Million)
  • TABLE 119. ROW enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
  • TABLE 120. ROW enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
  • TABLE 121. ROW enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)

Charts & Figures

  • FIG. 1 Top-down approach
  • FIG. 2 Data validation
  • FIG. 3 Fabry disease treatment industry 360 degree synopsis, 2017 - 2030
  • FIG. 4 Industry segmentation
  • FIG. 5 Global Fabry disease treatment market, by region, 2017 - 2030 (USD Million)
  • FIG. 6 Growth potential analysis, by treatment type
  • FIG. 7 Porter's analysis
  • FIG. 8 Company matrix analysis, 2021
  • FIG. 9 Global company share analysis, 2021
  • FIG. 10 North America market share analysis, 2021
  • FIG. 11 Europe market share analysis, 2021
  • FIG. 12 Asia Pacific market share analysis, 2021
  • FIG. 13 ROW market share analysis, 2021
  • FIG. 14 PESTEL analysis
  • FIG. 15 Key segment trends, by treatment type
  • FIG. 16 Key regional trends
  • FIG. 17 Strategy dashboard, 2021